This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D61.3 | Synonyms: Idiopathic aplastic anemia, aplastic anemia of unknown cause, severe aplastic anemia (SAA)
The history of idiopathic aplastic anemia begins with a case reported in 1888 by the German pathologist Paul Ehrlich: pancytopenia with complete loss of hematopoietic cells in the bone marrow and fatty replacement in a 29-year-old pregnant woman. Ehrlich described this as 'anemia due to loss of bone marrow function', and in 1904 Chauffard first used the name aplastic anemia.
In the mid-20th century, various chemicals such as chloramphenicol, benzene and anticancer drugs were found to be able to cause aplastic anemia. However, even after these causes were excluded, cases of unknown cause accounted for about 70–80% of the total, and these came to be classified as idiopathic aplastic anemia.
In 1976, Mathé et al. first reported the efficacy of ALG (anti-lymphocyte globulin), and the subsequent addition of cyclosporine greatly improved treatment outcomes. As a result, idiopathic aplastic anemia came to be understood mostly as immune-mediated destruction of hematopoietic progenitor cells by autoreactive T cells.
In Korea, the incidence of aplastic anemia is about 2–3 times higher than in Western countries. Large patient cohorts have been established at tertiary institutions such as Seoul National University, Yonsei University and The Catholic University of Korea, and domestic multicenter studies continue to report outcomes of immunosuppressive therapy and hematopoietic stem cell transplantation in Koreans.
The core cause of idiopathic aplastic anemia is destruction of hematopoietic progenitor cells (HSC/HSPC) by autoreactive CD8+ cytotoxic T lymphocytes and CD4+ T helper type 1 cells. These T cells secrete Th1 cytokines (IFN-γ, TNF-α, IL-2) and induce apoptosis of hematopoietic progenitor cells through the Fas-FasL pathway and the perforin/granzyme pathway.
A congenital genetic predisposition (such as telomere gene mutations) is identified in about 10–15% of all idiopathic aplastic anemia. Small PNH clones due to PIG-A mutations accompany about 50–60% of patients with idiopathic aplastic anemia.
By definition, idiopathic aplastic anemia is diagnosed after excluding specific causes of aplastic anemia such as drugs, radiation, toxins, viruses (EBV, HIV, hepatitis B virus, etc.) and pregnancy.
Associations with specific HLA alleles have been reported in idiopathic aplastic anemia. The HLA-DRB1*15:01 allele is associated with increased disease susceptibility in both East Asians and Europeans. HLA-DR2 and related haplotypes have also been identified as risk factors.
Various somatic clonal mutations are found in the residual hematopoietic progenitor cells of idiopathic aplastic anemia. Somatic mutations in DNMT3A, ASXL1, BCOR/BCORL1, RUNX1 and others are found, and some mutations are associated with response to immunosuppressive therapy and with the risk of malignant transformation (MDS/AML).
Telomere gene mutations (TERT, TERC, DKC1, RTEL1, etc.) are identified in about 10–15% of all patients with idiopathic aplastic anemia. These patients appear idiopathic but actually have a constitutional cause, which makes an important difference in the choice of treatment strategy.
The incidence of aplastic anemia overall, including idiopathic aplastic anemia, is 1–2 per million per year in Western countries and 3–8 per million in East Asia (Korea, Japan, China), markedly higher in East Asia. About 70–80% of all aplastic anemia is classified as idiopathic.
The age-of-onset distribution shows a bimodal distribution with two peaks, in the teens to twenties (children and young adults) and in those aged 60 and older (the elderly). There is no or only a slight sex difference.
The incidence of aplastic anemia in Korea is about 3–8 per million per year, higher than in Western countries, which is mainly related to the genetic susceptibility and environmental factors of East Asians. In Korea, about 70–80% of patients with aplastic anemia are idiopathic, and the number of patients managed in major domestic hematology departments reaches several thousand.
The core pathogenesis of idiopathic aplastic anemia is activation of oligoclonal autoreactive CD8+ T cells targeting hematopoietic progenitor cells (HSCs and early progenitors). These T cells recognize autoantigens on the surface of hematopoietic progenitor cells (not yet clearly identified) and induce apoptosis through the perforin/granzyme pathway and the Fas-FasL pathway.
Activated Th1 cells secrete IFN-γ, TNF-α and IL-2, making the bone marrow microenvironment suppressive of hematopoiesis. IFN-γ directly upregulates Fas expression on hematopoietic progenitor cells and promotes apoptosis. TNF-α suppresses the secretion of hematopoiesis-supporting factors by bone marrow stromal cells.
CD4+CD25+FoxP3+ regulatory T cells (Treg), which are responsible for normal immune regulation, have been reported to be numerically and functionally defective in patients with idiopathic aplastic anemia. Treg deficiency fails to suppress the activation of autoreactive T cells, leading to sustained destruction of hematopoietic progenitor cells.
Hematopoietic progenitor cells lacking GPI-anchored proteins (CD55, CD59, etc.) due to PIG-A mutations (PNH clones) evade recognition by autoreactive T cells and have a selective survival advantage in the autoimmune environment. As a result, small PNH clones are found in more than half of patients with idiopathic aplastic anemia.
Fatigue, weakness, pallor, dyspnea and palpitations are the main symptoms of anemia. Reduced exercise capacity, headache and decreased concentration accompany them. In severe anemia, dyspnea at rest and chest pain may occur.
Skin petechiae, purpura, easy bruising, gum bleeding, nosebleeds and menorrhagia are common. In severe thrombocytopenia, intracranial hemorrhage (a life-threatening emergency) may occur. Recurrent bacterial infections (pneumonia, sepsis), fever and oral ulcers appear. In severe neutropenia, fungal infections (aspergillosis, candidiasis) can be life-threatening.
When the PNH clone is significantly expanded, intravascular hemolysis (abdominal pain, dark urine, back pain) and thrombosis (deep vein thrombosis, intra-abdominal thrombosis) occur.
Pallor (conjunctival pallor, palmar pallor), petechiae, purpura, bruising and gum bleeding are the main physical examination findings. Splenomegaly and lymphadenopathy are generally absent; if present, other diagnoses (lymphoma, AML, etc.) should be considered. The absence of congenital anomalies distinguishes it from constitutional aplastic anemia.
Complete blood count shows pancytopenia (low Hb, thrombocytopenia, leukopenia). Diagnostic criteria for severe aplastic anemia (SAA): bone marrow cellularity below 25% + at least 2 of the following 3: ①ANC < 500/μL, ②platelets < 20,000/μL, ③absolute reticulocyte count < 40,000/μL. Very severe (VSAA): ANC < 200/μL.
Bone marrow aspiration and biopsy are characterized by markedly reduced cellularity (hypocellular marrow) and replacement by fat cells. High-sensitivity flow cytometry detects CD55-, CD59-, FLAER- cell clones (PNH clones), and the presence of a PNH clone is evidence supporting an immune pathogenesis.
When pancytopenia or cytopenia of two or more lineages is found, ①peripheral blood smear, ②reticulocyte count, ③bone marrow aspiration and biopsy and ④flow cytometry (PNH clone, HLA-DR15 expression) are performed.
Secondary causes are excluded with B12/folate deficiency testing, thyroid function, liver function tests, viral tests (EBV, CMV, HIV, hepatitis B and C viruses, Parvovirus B19), autoantibodies (ANA, anti-dsDNA), pregnancy testing (female patients), etc.
Screening for constitutional causes is essential, especially in patients younger than 35 or with a family history. DEB/MMC testing (to differentiate Fanconi anemia), telomere length measurement and an inherited bone marrow failure gene panel are performed.
The diagnosis of idiopathic aplastic anemia is a diagnosis of exclusion. Aplastic anemia is diagnosed when all of the following are met: ①hypocellular marrow (bone marrow cellularity < 25%) + ②pancytopenia (cytopenia of two or more lineages) + ③exclusion of other causes of cytopenia (no leukemia, MDS, inherited bone marrow failure or secondary cause); if no cause is identified, it is classified as idiopathic.
Non-severe (Non-SAA): SAA criteria not met. Severe (SAA): ANC < 500/μL + bone marrow cellularity < 25% + at least 2 of platelets < 20,000/μL or absolute reticulocyte count < 40,000/μL met. Very severe (VSAA): ANC < 200/μL.
Flow cytometry for PNH clones, HLA-DR15 typing, telomere length measurement, somatic mutation testing (DNMT3A, ASXL1, BCOR, etc.) and chromosome analysis (to check for abnormal clones) help with diagnosis and treatment planning.
In patients younger than 40 with severe/very severe aplastic anemia who have an HLA-matched sibling donor, HSCT is the first-line treatment. The standard regimen is fludarabine + cyclophosphamide-based conditioning. The 5-year overall survival of HLA-matched sibling HSCT is about 80–90%. Unrelated donor HSCT is also performed after failure of immunosuppressive therapy or in high-risk groups, and its outcomes are improving.
This is the standard treatment for patients who cannot undergo HSCT or for patients aged 40 and older. Recently, triple combination of ATG + cyclosporine A + eltrombopag has been adopted as standard, improving the response rate up to 94%.
Eltrombopag, a thrombopoietin (TPO) receptor agonist, is effective alone or in combination in patients with aplastic anemia refractory to ATG+CsA. It was approved by the US FDA for the treatment of aplastic anemia in 2014. Regular transfusion (red cells, platelets), G-CSF (in neutropenia), prophylactic antibiotics (including antifungals), oral hygiene and iron chelation (in chronically transfused patients) are the core of supportive care.
The 5-year overall survival after HLA-matched sibling HSCT is about 80–90%. The overall response rate after IST has improved to about 90–94% (triple combination of ATG+CsA+eltrombopag). Relapse occurs in about 30–40% after IST, requiring repeat IST or HSCT.
The most important long-term complication of idiopathic aplastic anemia is malignant transformation to MDS/AML. After IST, the 10-year cumulative incidence of MDS/AML is about 10–15%. Deletion of the short arm of chromosome 7 (monosomy 7) is the poorest prognostic marker.
According to domestic multicenter studies, the 5-year survival after HSCT in Korean patients with idiopathic aplastic anemia is reported to be about 80% or more, outcomes similar to those in Western countries. The IST response rate is also similar to international standards.
Because the cause of idiopathic aplastic anemia is unclear, primary prevention is difficult. Avoiding unnecessary use of drugs that can cause aplastic anemia (chloramphenicol, sulfonamides, etc.) and minimizing exposure to organic chemicals such as benzene and to radiation help reduce potential risk.
To prevent relapse after response to IST, cyclosporine A is maintained for at least 2 years and tapered gradually. Regular hematologic follow-up testing (every 3–6 months), bone marrow examination (surveillance for abnormal clones or malignant transformation) and PNH clone monitoring are recommended.
In neutropenic patients, prophylactic antifungals (fluconazole or posaconazole), prophylactic antivirals (acyclovir or valacyclovir) and Pneumocystis prophylaxis (TMP-SMX) are given. Live vaccines are avoided during immunosuppressive therapy, and the vaccination schedule is re-planned after completion of IST.